http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Human Motion Recognition Using Directional Motion History Images
Makoto Murakami,Joo Kooi Tan,Hyoungseop Kim,Seiji Ishikawa 제어로봇시스템학회 2010 제어로봇시스템학회 국제학술대회 논문집 Vol.2010 No.10
Nowadays many persons are needed to observe images from surveillance cameras, because many surveillance cameras are installed in a town or in buildings. They are working under strain, because they must always watch the images from surveillance cameras to find a person with abnormal motion. Therefore reduction of the load is necessary. Many existing researches on human motion recognition are only recognition and the information of the result is not used. We assume that human motion is a set of basic motions. So, an overall motion can be understood using the recognition result of basic motions. The goal of the present research is to develop a method of human motion representation and translation using directional motion history images (DMHIs). In this paper, we describe a method of recognizing basic motions using the DMHIs. We perform the recognition by the Histograms of Oriented Gradients (HOG) feature. In the experiment, the number of bins and local area (cell) sizes for calculating the HOG feature are changed and the most suitable values are inspected.
Murakami, Haruyasu,Nokihara, Hiroshi,Hayashi, Hidetoshi,Seto, Takashi,Park, Keunchil,Azuma, Koichi,Tsai, Chun‐,Ming,Yang, James Chih‐,Hsin,Nishio, Makoto,Kim, Sang‐,We,Kiura, Katsuyu John Wiley and Sons Inc. 2018 CANCER SCIENCE Vol.109 No.9
<P>Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer (NSCLC). ASP8273 is a highly specific, irreversible, once‐daily, oral, EGFR TKI that inhibits both activating and resistance mutations. This ASP8273 dose‐escalation/dose‐expansion study (NCT02192697) was undertaken in two phases. In phase I, Japanese patients (aged ≥20 years) with NSCLC previously treated with ≥1 EGFR TKI received escalating ASP8273 doses (25‐600 mg) to assess safety/tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) by the Bayesian Continual Reassessment Method. In phase II, adult patients with T790M‐positive NSCLC in Japan, Korea, and Taiwan received ASP8273 at RP2D to further assess safety/tolerability and determine antitumor activity, which was evaluated according to Simon's two‐stage design (threshold response = 30%, expected response = 50%, α = 0.05, β = 0.1). Overall, 121 (n = 45 [33W/12M] phase I, n = 76 [48W/28M]) phase 2) patients received ≥1 dose of ASP8273. In phase I, RP2D and MTD were established as 300 and 400 mg, respectively. As 27 of the 63 patients treated with ASP8273 300 mg achieved a clinical response, ASP8273 was determined to have antitumor activity. The overall response rate at week 24 in all patients was 42% (n = 32/76; 95% confidence interval, 30.9‐54.0). Median duration of progression‐free survival was 8.1 months (95% confidence interval, 5.6, upper bound not reached). The most commonly reported treatment‐related adverse event in phase II was diarrhea (57%, n = 43/76). ASP8273 300 mg was generally well tolerated and showed antitumor activity in Asian patients with both EGFR‐activating and T790M mutations.</P>
Autonomous Burst Access Control Cooperated with Adjacent Nodes in Wireless Multihop Networks
Yosuke Tanigawa,Makoto Mochiki,Hideki Tode,Koso Murakami 한국멀티미디어학회 2009 한국멀티미디어학회 국제학술대회 Vol.2009 No.-
The authors propose the packet transfer scheduling method to perform efficient data transfer in wireless multibop networks. In the proposed method, we set packet transfer rate, mainly according to the success rate of packet transfer at the sender nodes. In this paper, we consider the packet loads at the receiver nodes, and feed the load information back to the upstream nodes. Moreover, we assign channel resources equally to sender nodes that transfer packet to the same receiver node. Through these proposals, we enhance the network capacity keeping the throughput fairness between nodes.